Abdominal obesity

The results of ADAGIO-Lipids study suggests that rimonabant significantly improves cardiovascular and metabolic risk markers, such as reduced intra-abdominal, and liver fat content in patients with abdominal obesity. The study was published in Arteriosclerosis, Thrombosis and Vascular Biology. Its purpose was to investigate the effects of rimonabant on kardiometabolitni multiple risk factors in 803 patients with obesity and low HDL and high triglycerides levels. Participants were randomized to rimonabant 20 mg daily or placebo for one years. 231 patients were subjected to computed tomography to determine endokanabinoidniya effect on visceral and liver fat content. Dr. Jean-Pierre Despres and colleagues (Hopital Laval Research Centre) stressed that liver fat is a major metabolic risk factor that is independent of visceral fat.
Treatment with rimonabant resulted in significant increases in HDL-cholesterol by 7.4 percent compared to the base and reduce triglyceride levels by 18%. Active treatment led to lower LDL cholesterol, apolipoprotein A1, B, HDL2, HDL3, C-reactive protein and adiponektin. Patients in the active group observed a reduction of abdominal subcutaneous fat by 5.1%, and visceral fat - 10.1 percent compared with placebo. Systolic blood pressure in these patients decreased on average by 3.3 mm Hg, and diastolichnoto - with 2.4 mm Hg versus placebo group. The safety profile of rimonabant was favorable and similar to profiles found in previous studies. The study supports the theory that obesity is not a major problem, and where fat is located. The liver is rich in endokanabinoidni receptors effectively blocked by rimonabant, thus reducing liver fat. Rimonabant should not be viewed as another blockbuster * against obesity. This is a preparation to be used in the correct patient, and this is the patient with abdominal obesity and liver!

What is Psoriasis?

Psoriasis is a chronic, inflammatory disease. There are different methods of treatment, reduce severity of symptoms and improving quality of life of patients. In Bulgaria, the incidence of disease is 1% to 3% of the population. The etiology of psoriasis is unknown, it has been established hereditary predisposition. Inflammatory process and the involvement of the immune system take a major role in patogenetichnite mechanisms. Influence on climatic factors have a disease, injury, alcohol and certain medications, and mental stress. How to develop the disease? At the beginning appears okraglena red plate, which subsequently zadebelyava and covered with whitish scales. Most often concerning skin areas are the elbows, knees and scalp. Less Psoriasis affects the nails and joints - ie. psoriatic arthritis.
The top layer of skin consists of keratinizirali, dead cells are replaced constantly. New cells appear at the bottom (6azalen) layer and gradually move to the surface, such as over-extrude out underlying cells. In psoriatic skin this process is considerably shorter and the basal cells divide more quickly. Kerala-organized cells can not promptly disappear, leading to the formation of skvami (flakes). The disease runs a chronic relapsing-improvement and worsening during the summer in winter. How to treat this difficult izlechimabolest? Complete cure of psoriasis is very difficult to achieve. In his treatment, he often goes into a latent (hidden) period. This stage can last months, different times to years. Characteristic of psoriasis is that mainly affects the skin of the patient. But in the siege could lead to amendment of the joints. Psoriatic arthritis is usually seen after 3-5 years or more after onset of first symptoms. Larger share in the successful treatment of psoriasis is attributed to phytotherapy. Many plants, such as sar-saparila, burdock, etc.. May well affect the patient's subjective symptoms and stop progression of the disease. Therefore, doctors recommend the adoption of Psoriazal Plus - a product of "Vita Herb, developed specifically for psoriasis. Observations in humans receiving "Psoriazal Plus, show that 84 percent of people with psoriasis feel significant improvement in symptoms as early as the fourth week of administration.